Abstract
The invention provides monoclonal antibodies and antigen-binding fragments thereof specific for TNFR2, and methods of using the same to treat cancer or autoimmune disorder, including combination therapy with antagonists of the PD-1/PD-L1 immune checkpoint.
Full Text
What is claimed is:
The invention provides monoclonal antibodies and antigen-binding fragments thereof specific for TNFR2, and methods of using the same to treat cancer or autoimmune disorder, including combination therapy with antagonists of the PD-1/PD-L1 immune checkpoint.
Timeline
Filed
04/01/2026Published
07/23/2026Granted
Not AvailableIPC Codes(5)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61K 39/395:Antibodies (agglutinins A61K 38/36); Immunoglobulins; Immune serum, e.g. antilymphocytic serum